Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
19 studies found for:    Open Studies | "Pneumococcal Infections"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Pneumococcal Infections"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
Conditions: Streptococcus Pneumoniae Infection;   Pneumococcal Infections
Interventions: Biological: V114;   Biological: Prevnar 13
2 Recruiting Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Conditions: Pneumococcal Infections;   Pneumonia, Pneumococcal
Interventions: Biological: GEN-004 with Aluminum Hydroxide Adjuvant;   Biological: Placebo
3 Recruiting A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Condition: Pneumococcal Infection
Intervention: Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
4 Recruiting Aerosolized and Intravenous Colistin in Healthy Adults
Conditions: Pneumonia;   Pneumococcal Infection;   Pathogen Resistance
Intervention: Drug: Colistimethate sodium
5 Recruiting Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Conditions: HIV;   Pneumococcal Infections;   Pneumococcal Vaccines
Interventions: Biological: PCV-13;   Biological: PPSV-23
6 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection
Condition: Infections, Streptococcal
Intervention: Biological: Synflorix™
7 Not yet recruiting Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers
Condition: Pneumococcal Infection
Interventions: Biological: Pneumo 23® 0,5;   Biological: Pneumo 23® 0,1;   Biological: Prevenar13® 0,5
8 Not yet recruiting Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
Condition: Pneumococcal Infection
Intervention: Biological: PNEUMOVAX™ 23
9 Recruiting Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
Condition: Pneumococcal Infection
Interventions: Biological: PNEUMOVAX and PREVNAR;   Biological: Pneumovax or Prevnar
10 Recruiting A Study to Evaluate the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
Condition: Pneumococcal Infections
Interventions: Biological: Prevnar 13™;   Biological: Pneumovax™ 23;   Biological: Placebo
11 Not yet recruiting An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department
Condition: Pneumococcal Infections
Intervention:
12 Unknown  PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease
Conditions: Middle Ear Effusion;   Tympanic Membrane Perforation;   Acute Otitis Media;   Pneumococcal Infections
Intervention: Biological: 23 valent pneumococcal polysaccharide vaccine
13 Recruiting Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease
Conditions: Invasive Pneumococcal Infections;   Sickle Cells Disease
Interventions: Biological: Vaccination with the combined vaccine (Prevenar13 ®);   Biological: Vaccination with the polysaccharide vaccine (Pneumo 23 ®)
14 Recruiting Protection Against Pneumococcal Infection in Children With T1DM
Condition: Type 1 Diabetes Mellitus
Intervention: Biological: 13-valent pneumococcal conjugate vaccine (PCV13)
15 Not yet recruiting Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD
Conditions: Infections, Pneumococcal;   Bowel Diseases, Inflammatory
Interventions: Biological: Prevenar 13;   Biological: Pneumo 23
16 Recruiting Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.
Conditions: Seizures;   Pneumococcal Meningitis
Interventions: Drug: Phenytoin;   Drug: placebo
17 Recruiting Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
Condition: Pneumonia, Pneumococcal
Interventions: Biological: PATH-wSP;   Biological: pneumococcal polysaccharide conjugate vaccine (adsorbed);   Biological: Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate;   Other: Saline
18 Recruiting Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults
Condition: Splenectomized Patients
Intervention: Biological: Prime-boost pneumococcal immunization
19 Recruiting Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
Condition: Influenza
Interventions: Biological: Influsplit™ Tetra (Fluarix™ Tetra);   Biological: Pneumovax 23/Pneumovax;   Biological: Placebo

Indicates status has not been verified in more than two years